Valneva awaits EU COVID-19 vaccine decision
Valneva remains optimistic that its COVID-19 vaccine could get the green light in the EU in the near future.
Archives for April 28, 2022
Merck Q1: Keytruda sales up 23%
Merck’s cancer drug Keytruda continues to grow: helping Merck record ‘robust top-line and bottom-line growth’ across the company in Q1 2022.